Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) EBITDA Margin (2016 - 2025)

Cardiff Oncology's EBITDA Margin history spans 15 years, with the latest figure at 3220.99% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 510484.0% year-over-year to 3220.99%; the TTM value through Dec 2025 reached 8256.32%, down 114360.0%, while the annual FY2025 figure was 8256.32%, 113319.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 3220.99% at Cardiff Oncology, up from 9978.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 3220.99% in Q4 2025 and bottomed at 14964.86% in Q1 2022.
  • The 5-year median for EBITDA Margin is 8231.52% (2021), against an average of 9207.82%.
  • The largest annual shift saw EBITDA Margin skyrocketed 918731bps in 2024 before it crashed -786132bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 7162.41% in 2021, then fell by -2bps to 7337.5% in 2022, then increased by 10bps to 6623.08% in 2023, then fell by -26bps to 8325.83% in 2024, then surged by 61bps to 3220.99% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's EBITDA Margin are 3220.99% (Q4 2025), 9978.33% (Q3 2025), and 12212.4% (Q2 2025).